Glomerulonephritis with non-Randall-type, non-cryoglobulinaemic monoclonal immunoglobulin G deposits (PGNMID and ITG).
DNAJB9
PGNMID
electron microscopy
monoclonal gammopathy of renal significance
monoclonal immunoglobulin G
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
04
11
2021
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
26
8
2022
Statut:
epublish
Résumé
Glomerulonephritis (GN) with non-Randall-type, non-cryoglobulinaemic monoclonal immunoglobulin G deposits encompasses rare diseases [proliferative GN with non-organized deposits (PGNMID) and immunotactoid GN] that cannot be distinguished without ultrastructural analysis by electron microscopy (EM). Here, we report and analyse the prognosis of 41 EM-proven (PGNMID for 39/41) and 22 non-EM-proven/DNAJB9-negative cases, diagnosed between 2001 and 2019 in 12 French nephrology centres. Median (interquartile range) serum creatinine (SCr) at presentation was 150 (92-256) µmol/L. The predominant histological pattern was membranoproliferative GN (79%), with IgG3 (74%) kappa (78%) deposits the most frequently observed. Disease presentation and patient management were similar between EM-proven and non-EM-proven cases. A serum monoclonal spike was detected for 21 patients and 10 had an underlying haematological malignancy. First-line therapy was mixed between clone-targeted therapy ( Our results confirm that non-cryoglobulinaemic and non-Randall GN with monoclonal IgG deposits are rarely associated with haematological malignancy. The prognosis is uncertain but may be improved by early introduction of a specific therapy.
Sections du résumé
Background
UNASSIGNED
Glomerulonephritis (GN) with non-Randall-type, non-cryoglobulinaemic monoclonal immunoglobulin G deposits encompasses rare diseases [proliferative GN with non-organized deposits (PGNMID) and immunotactoid GN] that cannot be distinguished without ultrastructural analysis by electron microscopy (EM).
Methods
UNASSIGNED
Here, we report and analyse the prognosis of 41 EM-proven (PGNMID for 39/41) and 22 non-EM-proven/DNAJB9-negative cases, diagnosed between 2001 and 2019 in 12 French nephrology centres.
Results
UNASSIGNED
Median (interquartile range) serum creatinine (SCr) at presentation was 150 (92-256) µmol/L. The predominant histological pattern was membranoproliferative GN (79%), with IgG3 (74%) kappa (78%) deposits the most frequently observed. Disease presentation and patient management were similar between EM-proven and non-EM-proven cases. A serum monoclonal spike was detected for 21 patients and 10 had an underlying haematological malignancy. First-line therapy was mixed between clone-targeted therapy (
Conclusions
UNASSIGNED
Our results confirm that non-cryoglobulinaemic and non-Randall GN with monoclonal IgG deposits are rarely associated with haematological malignancy. The prognosis is uncertain but may be improved by early introduction of a specific therapy.
Identifiants
pubmed: 36003672
doi: 10.1093/ckj/sfac085
pii: sfac085
pmc: PMC9394706
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1727-1736Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.
Références
Kidney Int. 2016 Apr;89(4):897-908
pubmed: 26994577
J Clin Invest. 1970 Mar;49(3):610-21
pubmed: 5415687
Kidney Int Rep. 2019 Apr 29;4(7):917-922
pubmed: 31317113
Diagn Immunol. 1985;3(4):191-6
pubmed: 4085174
Kidney Int. 2018 Jul;94(1):199-205
pubmed: 29759418
Blood Cancer J. 2017 Aug 25;7(8):e590
pubmed: 28841203
Kidney Int. 2002 Nov;62(5):1764-75
pubmed: 12371978
Nephrol Dial Transplant. 2021 Jan 25;36(2):208-215
pubmed: 33494099
Kidney Int Rep. 2017 Aug 08;3(1):56-64
pubmed: 29340314
Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1741-1750
pubmed: 31685544
Am J Kidney Dis. 2007 Oct;50(4):641-4
pubmed: 17900464
J Exp Med. 1971 Feb 1;133(2):289-304
pubmed: 5133863
Nephrol Dial Transplant. 2012 Nov;27(11):4137-46
pubmed: 22872726
Nephrol Dial Transplant. 2011 Aug;26(8):2712-4
pubmed: 21633102
Am J Clin Pathol. 2012 Oct;138(4):609-13
pubmed: 23010717
Leukemia. 2017 Oct;31(10):2094-2103
pubmed: 28104919
Kidney Int Rep. 2021 Jan 28;6(4):936-945
pubmed: 33912743
Kidney Int. 2021 Feb;99(2):410-420
pubmed: 32818517
Clin J Am Soc Nephrol. 2011 Jan;6(1):122-32
pubmed: 20876681
N Engl J Med. 2002 Feb 21;346(8):564-9
pubmed: 11856795
Clin J Am Soc Nephrol. 2011 Jul;6(7):1609-16
pubmed: 21700823
Nat Rev Nephrol. 2019 Jan;15(1):45-59
pubmed: 30510265
J Am Soc Nephrol. 2009 Sep;20(9):2055-64
pubmed: 19470674
Kidney Int. 2020 Mar;97(3):589-601
pubmed: 32001067
Mol Immunol. 2015 Oct;67(2 Pt A):171-82
pubmed: 25900877
Kidney Int. 2021 Feb;99(2):421-430
pubmed: 32739419
Blood. 2013 Nov 21;122(22):3583-90
pubmed: 24108460
J Am Soc Nephrol. 2020 Oct;31(10):2400-2411
pubmed: 32747354
Kidney Int. 2017 Feb;91(2):423-434
pubmed: 27773425
Kidney Int. 2019 Feb;95(2):467-468
pubmed: 30665574
Mayo Clin Proc. 2015 May;90(5):587-96
pubmed: 25939936
Kidney Int. 2003 Apr;63(4):1450-61
pubmed: 12631361
Clin J Am Soc Nephrol. 2010 May;5(5):770-82
pubmed: 20185597
Kidney Int. 2004 Jan;65(1):85-96
pubmed: 14675039
J Nephrol. 2020 Jun;33(3):611-617
pubmed: 32221859